



Entheon Biomedical Announces Change of Officers

VANCOUVER, BC, July 31, 2023 – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“**Entheon**” or the “**Company**”) announces that the Company has terminated Andrew Hegle’s position as Chief Science Officer, effective today. Mr. Hegle will continue on the Company’s Board of Directors.

About Entheon Biomedical Corp.

Entheon is a biotechnology research and development company interested in treating addiction and substance use disorders.

On Behalf of the Board of Directors,

Timothy Ko, CEO, President and Director

For more information, please contact the Company at:

Entheon Biomedical Corp.

Timothy Ko, CEO

timothy@entheonbiomedical.com

<https://entheonbiomedical.com>